Trastuzumab deruxtecan has shown efficacy in patients with previously treated human epidermal growth factor receptor 2 (HER2)–positive advanced or metastatic breast cancer. The efficacy and safety of ...
News Medical: THP regimen achieves high response rates in HER2 positive breast cancer patients
THP regimen achieves high response rates in HER2 positive breast cancer patients
CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...
Each year 4 February is commemorated as World Cancer Day. Today marks twenty-five years of signing the Charter of Paris Against Cancer at the World Summit Against Cancer for the New Millenium. On this year’s World Cancer Day themed United by Unique, which is a reminder of the collective commitment against cancer, WHO acknowledges every patient’s unique experiences and the value of people ...
HER2-positive breast cancer is driven by HER2 protein overexpression, historically linked to poor outcomes but now improved by targeted therapies. Treatment varies by stage, involving surgery, ...
The New England Journal of Medicine: Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
FiercePharma: Pfizer scores again in HER2-positive breast cancer, this time with Seagen's Tukysa
Pfizer's oncology portfolio has produced a second positive phase 3 trial in HER2-positive breast cancer in the span of about a year. This time, the drug that delivered the positive readout is Tukysa, ...
Pfizer scores again in HER2-positive breast cancer, this time with Seagen's Tukysa
Patients with Stage II and III (early-stage) HER2+ breast cancer usually undergo pre-operative therapy with multi-agent chemotherapy in combination with anti-HER2 antibodies, followed by surgery. A ...